Hennig Arzneimittel &Kg

Executive Summary

Hennig Arzneimittel GmbH & Co. KG is a privately held, family-owned German pharmaceutical company with over 75 years of history. Founded in 1946 and headquartered in Flörsheim am Main, the company operates in two core segments: developing and marketing its own portfolio of generic drugs and over-the-counter (OTC) health products, and providing contract development and manufacturing organization (CDMO) services for solid oral dosage forms. With a heritage spanning more than 125 years of pharmaceutical manufacturing, Hennig has established itself as a reliable mid-sized player in the European generic and CDMO markets. The company's independence and focus on quality allow it to serve both its proprietary brands and external clients, though its small scale limits competitive intensity against larger multinationals. In the generic drugs space, Hennig benefits from steady demand for affordable medications, while its CDMO segment offers growth potential through partnerships with innovator companies seeking flexible manufacturing capacity. However, as a private company with no public disclosures, detailed financial and pipeline information is limited. The company's outlook depends on its ability to expand its product portfolio and CDMO client base in an increasingly consolidated industry. Overall, Hennig represents a stable but low-growth opportunity within the generic pharmaceutical sector, with conviction tempered by limited transparency and scale.

Upcoming Catalysts (preview)

• Q4 2026New Generic Product Approval or Launch60% success
• Q3 2026CDMO Capacity Expansion or Major Contract Win50% success
• TBDStrategic Partnership or Licensing Deal for OTC Products45% success